Jun 3, 2026 09:02AM
Jun 3, 2026 09:00AM
May 19, 2026 04:30PM
May 7, 2026 08:30AM
May 7, 2026 08:30AM
Apr 30, 2026 08:30AM
Apr 30, 2026 08:30AM Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
Mar 31, 2026 08:45AM
Mar 31, 2026 08:45AM
Mar 12, 2026 08:00AM
Mar 2, 2026 08:01AM
Mar 2, 2026 08:00AM
Feb 24, 2026 08:30AM
Feb 24, 2026 08:30AM Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement
Jan 12, 2026 08:02AM
Jan 12, 2026 08:00AM
Dec 11, 2025 08:05AM
Dec 11, 2025 08:05AM
Aug 5, 2025 06:01AM
Aug 5, 2025 06:00AM
May 8, 2025 08:00AM Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
Mar 13, 2025 04:05PM
Jan 9, 2025 08:44AM
Dec 31, 2024 08:00AM
Nov 12, 2024 09:00AM
Nov 7, 2024 09:00AM
Aug 22, 2024 09:03AM
Aug 22, 2024 09:00AM Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients
Aug 20, 2024 09:00AM
Aug 14, 2024 09:00AM
Aug 7, 2024 04:05PM
Aug 6, 2024 09:00AM
Jul 17, 2024 09:00AM
Jun 11, 2024 04:15PM
Jun 3, 2024 09:00AM Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients
May 23, 2024 09:00AM
May 9, 2024 09:00AM
Apr 11, 2024 04:30PM
Apr 9, 2024 09:05AM
Apr 9, 2024 09:00AM
Mar 11, 2024 09:00AM
Feb 26, 2024 09:00AM Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference
Feb 8, 2024 09:02AM
Feb 8, 2024 09:00AM
Jan 31, 2024 09:00AM
Dec 12, 2023 09:03AM
Dec 12, 2023 09:00AM
Nov 20, 2023 06:16AM
Oct 16, 2023 08:38AM Innovation Takes Center Stage: Florida's Life Sciences Leaders Shine at BioFlorida Conference
Jul 24, 2023 09:01AM

322,206 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All